pharmaceuticals

MNCs in the News-2020-02-14

JPMorgan (China) intends to assume full ownership of all its mainland China operations by 2021 to take advantage of China’s financial sector opening. Chinese regulators approve United States (US) credit card firm Mastercard Inc.’s application to establish a bankcard clearing house joint venture. Peter Navarro urges the US to reduce its reliance on Chinese pharmaceutical and medical supplies. New US regulations expanding the authority of the Committee on Foreign Investment in the United States (CFIUS) with respect to the review of foreign direct investment (FDI) have gone into effect, with notable implications for Chinese FDI in the US. Coronavirus impact on supply chains and production in China accelerates move already occurring because of US-China trade war and rising labor costs in China. Japan is excluded from list of countries exempted from new CFIUS review ambit, but this may change. Merger of Korean shipbuilding giants potentially affected by Japanese filing of World Trade Organization petition, charging illegal subsidies. Korea’s SK Engineering & Construction wins mega-deal to build a beltway in Kazakhstan.

Dr. Jean-Marc F. Blanchard's picture

Getting High on China: The High Cost of Low-Priced Drugs for Pharma Firms?

Recently, foreign pharmaceutical makers such as AbbVie, AstraZeneca, Novartis, Sanofi, and Roche slashed the prices of a large number of drugs sold in China, the world’s second largest drug market.

Dr. Jean-Marc F. Blanchard's picture

The Free Trade Zone that Ate Shanghai

The Shanghai Free Trade Zone (SFTZ) came into being in 2013. Since its birth, it has scored accomplishments such as faster customs processing times and easier business establishment.

Dr. Hwy-Chang Moon's picture

Korea’s Growing FDI in the ASEAN Healthcare Sector

The demand for healthcare is growing rapidly in the Association of Southeast Asian Nations (ASEAN), driven by ageing populations and rising incomes.

MNCs in the News-2019-05-31

Foreign direct investment (FDI) and domestic firms, lured by, respectively, China’s consumer stimulus and attractive valuations may mitigate the adverse effects of the US-China trade war on China. The trade war and new regulatory environment is driving Fosun to limit its investments in United States (US) biotech companies and to turn its attention to emerging markets. Namibia amenable to China National Uranium Corporation taking over the world’s longest-running open pit uranium mine provided it respects Namibian employment laws. Japan tightens restrictions on FDI in its high-tech sectors. Japan’s Inpex Corp. strikes USD $20 billion framework deal with Indonesia to develop an onshore liquefied natural gas facility. Large Korean companies remain on the sidelines in the wake of the US’s action to limit the supply of parts to China’s Huawei. To protect their interests in China, Korean firms are courting Chinese party leaders, forming joint ventures, and investing billions of dollars in Chinese high-tech sectors.